Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $40 to $39.
Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $40 to $39.